Direct Reprogramming Of Adult Cells: Avoiding T...

Enlisting New Teachers In Clinical Education

Is Hashimoto’s Thyroiditis A Risk Factor For ...

Programmable It Pumps

Hypertension- A Paradox-the Challenges And Newe...

0 votes
Paraoxonase: The Boon Against Oxidative Stress And Lipid Peroxidation
Author: Arun Kumar
Publisher: Internet Medical Publishing
3 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
DOI: 10.3823/1012
Follow this publisher

Share this publication:


Coronary Artery disease (CAD) is estimated to be the number one cause of morbidity and mortality in the developing world. It is a multifactorial disease and diet plays an important role the development of CAD, and the risk further increases in the presence of dyslipidaemia.

 The lipoprotein profile is found to be deranged mostly in CAD. Low density lipoprotein cholesterol (LDL) is considered as the most important risk factor of CAD. However, a significant proportion of patients have a normal lipid profile. The oxidation of LDL is believed to have a central role in atherogenesis. The HDL associated paraoxonase (PON1) enzyme is known to have protective effects on lipid peroxidation. High density cholesterol associated PON which is known to have cardio protective properties have antiatherogenic role and low PON1 activity could be an independent risk factor. 

Apart from prevention of oxidation in circulating lipid molecules, it proves to be beneficial in various disorders related to imbalance in oxidants and antioxidants. Serum paraoxonase activity is also affected in cardiovascular diseases, cancer, diabetes, hypertension, renal failure, smokers and gastrointestinal disorders. The dietary factor which contributes to increase in paraoxonase activity in serum includes consumption of polyphenolrich diets, wine and fruit juice consumption as it contains polyphenols. 

Since we have long noted the advances and understanding the physiological benefits of PON based on extensive research. We look forward for further updates in researches based on PONs and wait for the anti-aging capsules of PON being marketed by pharmaceutical companies.

About the publisher:

iMedPub Limited is a publishing house registered in UK, publishing medical books and journals since 2005. As an open service to doctors and biomedical researchers, it is driven by clinicians and researchers for themselves, while serving the interests of the general public. iMedPub disseminates research in a tiered system, beginning with our specialty books and journals and then working upwards. The grand vision of iMedPub is a world where all medical researchers and health professionals have an equal opportunity to seek, share and create knowledge. As we are a low cost academic publisher we offer the lowest article processing charges of all biomedical journals and publish books free of charges for authors.

Select a payment method